Aclarion, Inc.
ACON Nasdaq· Services-Medical Laboratories
Last close · Oct 26, 2026
$1.93
KIRA · Stoqly’s AI analyst, in plain words
- Aclarion, Inc. had $0.1M of revenue in fiscal 2025, up 65.6% on the year before.
- Its operating margin was −9,316.2%, up 2,747.2 pts: of every 100 in sales, about −9,316 is left after running the business.
- Aclarion, Inc. lost $7.2M in fiscal 2025.
- Free cash flow was −$7.2M in fiscal 2025, −9,492.3% of revenue.
Market cap
$4.8M
P/E
—
Revenue
$0.1M
Net income
−$7.2M
Free cash flow
−$7.2M
Operating margin
−9,316.2%
Aclarion, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+65.6%
Yes. Sales grew 65.6% last year.
Does it make a profit?
−9,555.6%
No. It lost money last year.
Does profit turn into cash?
−9,492.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Aclarion, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 18, 2026
- Legal name
- Aclarion, Inc.
- CIK
- 0001635077
Aclarion, Inc. · ACON
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.1M | $0.1M | $0.1M | $0.0M | $0.1M |
| Revenue growth | — | 0.2% | 24.8% | −39.4% | 65.6% |
| Gross margin | −14.8% | −8.1% | −0.4% | −85.1% | 9.0% |
| Operating margin | −4,897.2% | −9,207.9% | −6,466.8% | −12,063.5% | −9,316.2% |
| Net income | −$5.0M | −$7.1M | −$4.9M | −$7.0M | −$7.2M |
| Net margin | −8,209.5% | −11,703.0% | −6,513.8% | −15,301.8% | −9,555.6% |
| Diluted EPS | −$6.58 | −$19.61 | −$79,782.00 | −$7,478.90 | −$13.61 |
| Cash | |||||
| Cash from operations | −$2.4M | −$4.9M | −$3.6M | −$5.3M | −$7.2M |
| Capital expenditure | — | — | $0.0M | $0.0M | $0.0M |
| Free cash flow | — | — | −$3.6M | −$5.3M | −$7.2M |
| FCF margin | — | — | −4,836.7% | −11,546.4% | −9,492.3% |
| Share buybacks | $0.1M | — | — | — | — |
| Share count change | — | −57.9% | −100.0% | 800.0% | 59,011.1% |
| Debt and strength | |||||
| Cash and short-term investments | $0.4M | $1.5M | $1.0M | $0.5M | $12.0M |
| Deposits | — | — | — | $0.5M | — |
| Shareholders' equity | −$12.8M | $2.2M | −$0.7M | $1.0M | $12.8M |
| Current ratio | 0.1x | 2.5x | 0.4x | 0.7x | 14.8x |
| Interest coverage | −6.2x | −3.7x | −44.1x | −86.0x | — |
| Returns and quality | |||||
| Return on equity | — | — | −655.7% | −5,776.9% | −104.8% |
| Return on tangible equity | — | −736.8% | — | — | −62.5% |
| Piotroski F-score | — | 5 | 5 | 2 | 4 |
| Altman Z'' | −91.2 | −51.2 | −77.3 | −96.3 | 4.2 |
Insiders bought, 12 months
$0.2M
7 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Aclarion, Inc. · ACON
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.93 a share, the company is worth $4.8M.
Source: SEC EDGAR XBRL filings (CIK 0001635077). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.